Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease with a high symptom burden and poor quality of life. Treatment options include recurrent surgeries and/or frequent systemic corticosteroids (SCS). Dupilumab, a fully human monoclonal antibody, blocks the shared recept...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Rhinology Ročník 59; číslo 3; s. 301
Hlavní autoři: Desrosiers, M, Mannent, L P, Amin, N, Canonica, G W, Hellings, P W, Gevaert, P, Mullol, J, Lee, S E, Fujieda, S, Han, J K, Hopkins, C, Fokkens, W, Jankowski, R, Cho, S H, Mao, X, Zhang, M, Rice, M S, Khan, A H, Kamat, S, Patel, N, Graham, N M H, Ruddy, M, Bachert, C
Médium: Journal Article
Jazyk:angličtina
Vydáno: Netherlands 01.01.2021
Témata:
Adrenal Cortex Hormones
Adult
Antibodies, Monoclonal, Humanized
Chronic Disease
Double-Blind Method
Humans
Interleukin-13
Nasal Polyps - drug therapy
Nasal Polyps - surgery
Quality of Life
Rhinitis - complications
Rhinitis - drug therapy
Rhinitis - surgery
Treatment Outcome
ISSN:0300-0729
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease with a high symptom burden and poor quality of life. Treatment options include recurrent surgeries and/or frequent systemic corticosteroids (SCS). Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2-mediated inflammation. We report results of pooled analyses from 2 randomised, double-blind, placebo-controlled phase 3 studies (SINUS 24 [NCT02912468]; SINUS-52 [NCT02898454]) to evaluate dupilumab effect versus placebo in adults with CRSwNP with/without SCS use and sinonasal surgery. SINUS-24 patients were randomised 1:1 to subcutaneous dupilumab 300 mg (n=143) or placebo (n=133) every 2 weeks (q2w) for 24 weeks. SINUS-52 patients were randomised 1:1:1 to 52 weeks of subcutaneous dupilumab 300 mg q2w (n=150), 24 weeks q2w followed by 28 weeks of dupilumab 300 mg every 4 weeks (n=145) or 52 weeks of placebo q2w (n=153). Dupilumab reduced the number of patients undergoing sinonasal surgery (82.6%), the need for in-study SCS use (73.9%), and SCS courses (75.3%). Significant improvements were observed with dupilumab vs placebo regardless of prior sinonasal surgery or SCS use in nasal polyp, nasal congestion, Lund-MacKay, and Sinonasal Outcome Test (22-items) scores, and the University of Pennsylvania Smell Identification Test. Dupilumab demonstrated significant improvements in disease signs and symptoms and reduced the need for sino-nasal surgery and SCS use versus placebo in patients with severe CRSwNP, regardless of SCS use in the previous 2 years, or prior sinonasal surgery.
AbstractList Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease with a high symptom burden and poor quality of life. Treatment options include recurrent surgeries and/or frequent systemic corticosteroids (SCS). Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2-mediated inflammation. We report results of pooled analyses from 2 randomised, double-blind, placebo-controlled phase 3 studies (SINUS 24 [NCT02912468]; SINUS-52 [NCT02898454]) to evaluate dupilumab effect versus placebo in adults with CRSwNP with/without SCS use and sinonasal surgery. SINUS-24 patients were randomised 1:1 to subcutaneous dupilumab 300 mg (n=143) or placebo (n=133) every 2 weeks (q2w) for 24 weeks. SINUS-52 patients were randomised 1:1:1 to 52 weeks of subcutaneous dupilumab 300 mg q2w (n=150), 24 weeks q2w followed by 28 weeks of dupilumab 300 mg every 4 weeks (n=145) or 52 weeks of placebo q2w (n=153). Dupilumab reduced the number of patients undergoing sinonasal surgery (82.6%), the need for in-study SCS use (73.9%), and SCS courses (75.3%). Significant improvements were observed with dupilumab vs placebo regardless of prior sinonasal surgery or SCS use in nasal polyp, nasal congestion, Lund-MacKay, and Sinonasal Outcome Test (22-items) scores, and the University of Pennsylvania Smell Identification Test. Dupilumab demonstrated significant improvements in disease signs and symptoms and reduced the need for sino-nasal surgery and SCS use versus placebo in patients with severe CRSwNP, regardless of SCS use in the previous 2 years, or prior sinonasal surgery.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease with a high symptom burden and poor quality of life. Treatment options include recurrent surgeries and/or frequent systemic corticosteroids (SCS). Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2-mediated inflammation. We report results of pooled analyses from 2 randomised, double-blind, placebo-controlled phase 3 studies (SINUS 24 [NCT02912468]; SINUS-52 [NCT02898454]) to evaluate dupilumab effect versus placebo in adults with CRSwNP with/without SCS use and sinonasal surgery.BACKGROUNDChronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease with a high symptom burden and poor quality of life. Treatment options include recurrent surgeries and/or frequent systemic corticosteroids (SCS). Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2-mediated inflammation. We report results of pooled analyses from 2 randomised, double-blind, placebo-controlled phase 3 studies (SINUS 24 [NCT02912468]; SINUS-52 [NCT02898454]) to evaluate dupilumab effect versus placebo in adults with CRSwNP with/without SCS use and sinonasal surgery.SINUS-24 patients were randomised 1:1 to subcutaneous dupilumab 300 mg (n=143) or placebo (n=133) every 2 weeks (q2w) for 24 weeks. SINUS-52 patients were randomised 1:1:1 to 52 weeks of subcutaneous dupilumab 300 mg q2w (n=150), 24 weeks q2w followed by 28 weeks of dupilumab 300 mg every 4 weeks (n=145) or 52 weeks of placebo q2w (n=153).METHODOLOGYSINUS-24 patients were randomised 1:1 to subcutaneous dupilumab 300 mg (n=143) or placebo (n=133) every 2 weeks (q2w) for 24 weeks. SINUS-52 patients were randomised 1:1:1 to 52 weeks of subcutaneous dupilumab 300 mg q2w (n=150), 24 weeks q2w followed by 28 weeks of dupilumab 300 mg every 4 weeks (n=145) or 52 weeks of placebo q2w (n=153).Dupilumab reduced the number of patients undergoing sinonasal surgery (82.6%), the need for in-study SCS use (73.9%), and SCS courses (75.3%). Significant improvements were observed with dupilumab vs placebo regardless of prior sinonasal surgery or SCS use in nasal polyp, nasal congestion, Lund-MacKay, and Sinonasal Outcome Test (22-items) scores, and the University of Pennsylvania Smell Identification Test.RESULTSDupilumab reduced the number of patients undergoing sinonasal surgery (82.6%), the need for in-study SCS use (73.9%), and SCS courses (75.3%). Significant improvements were observed with dupilumab vs placebo regardless of prior sinonasal surgery or SCS use in nasal polyp, nasal congestion, Lund-MacKay, and Sinonasal Outcome Test (22-items) scores, and the University of Pennsylvania Smell Identification Test.Dupilumab demonstrated significant improvements in disease signs and symptoms and reduced the need for sino-nasal surgery and SCS use versus placebo in patients with severe CRSwNP, regardless of SCS use in the previous 2 years, or prior sinonasal surgery.CONCLUSIONSDupilumab demonstrated significant improvements in disease signs and symptoms and reduced the need for sino-nasal surgery and SCS use versus placebo in patients with severe CRSwNP, regardless of SCS use in the previous 2 years, or prior sinonasal surgery.
Author Hopkins, C
Cho, S H
Bachert, C
Gevaert, P
Amin, N
Fujieda, S
Mao, X
Mullol, J
Han, J K
Jankowski, R
Mannent, L P
Hellings, P W
Desrosiers, M
Fokkens, W
Kamat, S
Ruddy, M
Canonica, G W
Rice, M S
Graham, N M H
Zhang, M
Khan, A H
Lee, S E
Patel, N
Author_xml – sequence: 1
  givenname: M
  surname: Desrosiers
  fullname: Desrosiers, M
  organization: Centre de recherche du Centre hospitalier de l’Universite de Montreal (CRCHUM), Montreal, QC, Canada
– sequence: 2
  givenname: L P
  surname: Mannent
  fullname: Mannent, L P
  organization: Sanofi, Chilly-Mazarin, France
– sequence: 3
  givenname: N
  surname: Amin
  fullname: Amin, N
  organization: Regeneron Pharmaceuticals, Inc. Tarrytown, NY, USA
– sequence: 4
  givenname: G W
  surname: Canonica
  fullname: Canonica, G W
  organization: Regeneron Pharmaceuticals, Inc. Tarrytown, NY, USA
– sequence: 5
  givenname: P W
  surname: Hellings
  fullname: Hellings, P W
  organization: University Hospitals Leuven, Leuven, Belgium
– sequence: 6
  givenname: P
  surname: Gevaert
  fullname: Gevaert, P
  organization: Ghent University, Ghent, Belgium
– sequence: 7
  givenname: J
  surname: Mullol
  fullname: Mullol, J
  organization: Hospital Clinic, IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain
– sequence: 8
  givenname: S E
  surname: Lee
  fullname: Lee, S E
  organization: University of Pittsburgh Medical Center, Pittsburgh, PA, USA
– sequence: 9
  givenname: S
  surname: Fujieda
  fullname: Fujieda, S
  organization: University of Fukui, Fukui, Japan
– sequence: 10
  givenname: J K
  surname: Han
  fullname: Han, J K
  organization: Eastern Virginia Medical School, Norfolk, VA, USA
– sequence: 11
  givenname: C
  surname: Hopkins
  fullname: Hopkins, C
  organization: Guy's and St Thomas' Hospitals, London, UK
– sequence: 12
  givenname: W
  surname: Fokkens
  fullname: Fokkens, W
  organization: Academic Medical Center, Amsterdam, Netherlands
– sequence: 13
  givenname: R
  surname: Jankowski
  fullname: Jankowski, R
  organization: University Hospital of Nancy, University of Lorraine, Nancy, France
– sequence: 14
  givenname: S H
  surname: Cho
  fullname: Cho, S H
  organization: University of South Florida, Tampa, FL, USA
– sequence: 15
  givenname: X
  surname: Mao
  fullname: Mao, X
  organization: Sanofi, Bridgewater, NJ, USA
– sequence: 16
  givenname: M
  surname: Zhang
  fullname: Zhang, M
  organization: Sanofi, Bridgewater, NJ, USA
– sequence: 17
  givenname: M S
  surname: Rice
  fullname: Rice, M S
  organization: Sanofi, Cambridge, MA, USA
– sequence: 18
  givenname: A H
  surname: Khan
  fullname: Khan, A H
  organization: Sanofi, Chilly-Mazarin, France
– sequence: 19
  givenname: S
  surname: Kamat
  fullname: Kamat, S
  organization: Regeneron Pharmaceuticals, Inc. Tarrytown, NY, USA
– sequence: 20
  givenname: N
  surname: Patel
  fullname: Patel, N
  organization: Sanofi, Bridgewater, NJ, USA
– sequence: 21
  givenname: N M H
  surname: Graham
  fullname: Graham, N M H
  organization: Regeneron Pharmaceuticals, Inc. Tarrytown, NY, USA
– sequence: 22
  givenname: M
  surname: Ruddy
  fullname: Ruddy, M
  organization: Regeneron Pharmaceuticals, Inc. Tarrytown, NY, USA
– sequence: 23
  givenname: C
  surname: Bachert
  fullname: Bachert, C
  organization: Ghent University, Ghent, Belgium; Karolinska Institutet, Stockholm, Sweden; Sun Yat-sen University, First Affiliated Hospital, Guangzhou, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33847325$$D View this record in MEDLINE/PubMed
BookMark eNo1UMtOwzAQ9KGIPuDCByAfuQTWdpw0R1QoIFWACpyjjb0BozyKHQv17wminGZGGs3szpxNur4jxs4EXKaiUFfbD9fJX64nbAYKIIFcFlM2D-ETQGmQ4phNlVqmuZJ6xrY3ceea2GLFPdloKPCwDwO1znDT-8GZflS-d5bHQBw7y4MbOzFgw0P07-T33ONA3HV8tX35fnw-YUc1NoFOD7hgb-vb19V9snm6e1hdbxKTynxITJbqCq2ylkxmAKtsiVgrbSAvxpOXaCkv0lpnRlZGgCwgrQ2QRFuBUDXKBbv4y935_itSGMrWBUNNgx31MZRSCzk-mhditJ4frLFqyZY771r0-_J_B_kDnAdgAA
CitedBy_id crossref_primary_10_1007_s00106_024_01430_1
crossref_primary_10_1007_s11882_025_01192_y
crossref_primary_10_1002_clt2_70051
crossref_primary_10_1155_2023_4027701
crossref_primary_10_3389_falgy_2025_1573764
crossref_primary_10_2147_JAA_S420140
crossref_primary_10_1111_all_15796
crossref_primary_10_1111_all_15772
crossref_primary_10_1186_s13223_023_00780_9
crossref_primary_10_1080_07853890_2024_2411018
crossref_primary_10_1002_lio2_857
crossref_primary_10_1007_s00106_025_01635_y
crossref_primary_10_1080_17512433_2025_2468970
crossref_primary_10_1080_1744666X_2023_2232115
crossref_primary_10_1080_1744666X_2025_2459929
crossref_primary_10_1002_lary_30983
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.4193/Rhin20.415
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Anatomy & Physiology
ExternalDocumentID 33847325
Genre Randomized Controlled Trial
Clinical Trial, Phase III
Journal Article
GroupedDBID ---
123
ABATV
ABOCM
AENEX
AFOSN
ALMA_UNASSIGNED_HOLDINGS
CGR
CUY
CVF
EBD
EBS
ECM
EIF
EJD
EMB
EMOBN
F5P
NPM
NQS
OK1
P2P
SJN
SV3
7X8
ID FETCH-LOGICAL-c427t-c645bad3ddec6c0ab68aaf35c0797298ade794f56c2bc102904fc0e2adb013fa2
IEDL.DBID 7X8
ISICitedReferencesCount 64
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000659140700010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0300-0729
IngestDate Sun Nov 09 09:50:58 EST 2025
Mon Jul 21 05:57:48 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c427t-c645bad3ddec6c0ab68aaf35c0797298ade794f56c2bc102904fc0e2adb013fa2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://www.rhinologyjournal.com/download.php?id=2765
PMID 33847325
PQID 2512338791
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2512338791
pubmed_primary_33847325
PublicationCentury 2000
PublicationDate 2021-01-01
PublicationDateYYYYMMDD 2021-01-01
PublicationDate_xml – month: 01
  year: 2021
  text: 2021-01-01
  day: 01
PublicationDecade 2020
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Rhinology
PublicationTitleAlternate Rhinology
PublicationYear 2021
SSID ssj0035021
Score 2.4955947
Snippet Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease with a high symptom burden and poor quality of life. Treatment options...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 301
SubjectTerms Adrenal Cortex Hormones
Adult
Antibodies, Monoclonal, Humanized
Chronic Disease
Double-Blind Method
Humans
Interleukin-13
Nasal Polyps - drug therapy
Nasal Polyps - surgery
Quality of Life
Rhinitis - complications
Rhinitis - drug therapy
Rhinitis - surgery
Treatment Outcome
Title Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP
URI https://www.ncbi.nlm.nih.gov/pubmed/33847325
https://www.proquest.com/docview/2512338791
Volume 59
WOSCitedRecordID wos000659140700010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELaAMrDwKo_ykpEQm9U87DiZUFWoGCCqykPdIsd2RAbSUrcg_j1nJ4UJCYkliiIljs7n8_fd-e4QugDmH0Wx1IRL4CY0jzQRVDGSJIzpwit07iKmz3c8TePxOBk2DjfTHKtc2kRnqNVEWh951-7DQKd44l9N34jtGmWjq00LjVXUCgHKWK3m4-8oQsg8l3cFeuwRWyG7Lk9KAbN0Ry9lFdh79ju0dFvMYOu_P7eNNhtwiXu1NuygFV3tonavAmL9-okvsTvu6fzobTS6XkxLsEwixzNbvlUbXFd1LiUGRgpfsOkfs0mp8MJoLCqFTVkBbjcwgqmTqbGtM4HLCvdHDx_pcA89DW4e-7ekabBAJA34nMiIslyoEEycjKQn8igWogiZ9HgC4oqF0rBcCxbJIJeARBKPFtLTgVDWe1qIYB-twcD6EOFCAXDhvm_tFSAwHyadai1jX-SWQuoOOl9KLgMFtlEJUenJwmQ_suugg1r82bSutJHBc8rDgB394e1jtBHY8ybOPXKCWgUsX32K1uX7vDSzM6cZcE2H9183oMUC
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dupilumab+reduces+systemic+corticosteroid+use+and+sinonasal+surgery+rate+in+CRSwNP&rft.jtitle=Rhinology&rft.au=Desrosiers%2C+M&rft.au=Mannent%2C+L+P&rft.au=Amin%2C+N&rft.au=Canonica%2C+G+W&rft.date=2021-01-01&rft.issn=0300-0729&rft.volume=59&rft.issue=3&rft.spage=301&rft_id=info:doi/10.4193%2FRhin20.415&rft_id=info%3Apmid%2F33847325&rft_id=info%3Apmid%2F33847325&rft.externalDocID=33847325
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0300-0729&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0300-0729&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0300-0729&client=summon